Approach to relapsed CLL including Richter Transformation

被引：2
|
作者：
Seymour, John F. [1 ,2 ]
机构：
[1] Univ Melbourne, Royal Melbourne Hosp, Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Ctr, Dept Haematol, 305 Grattan St, Melbourne, VIC 3000, Australia
来源：
HEMATOLOGICAL ONCOLOGY | 2023年 / 41卷
关键词：
acalabrutinib; chronic lymphocytic leukemia; ibrutinib; relapse; Richter transformation; treatment sequencing; Venetoclax; zanubrutinib; CHRONIC LYMPHOCYTIC-LEUKEMIA; VENETOCLAX PLUS RITUXIMAB; OPEN-LABEL; MUTATIONS; MECHANISMS; IDELALISIB; RESISTANCE; SURVIVAL; EFFICACY; THERAPY;
D O I：
10.1002/hon.3146
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：136 / 143
页数：8
相关论文
共 50 条
  • [1] Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL
    Ding, Wei
    LaPlant, Betsy R.
    Call, Timothy G.
    Parikh, Sameer A.
    Leis, Jose F.
    He, Rong
    Shanafelt, Tait D.
    Sinha, Sutapa
    Le-Rademacher, Jennifer
    Feldman, Andrew L.
    Habermann, Thomas M.
    Witzig, Thomas E.
    Wiseman, Gregory A.
    Lin, Yi
    Asmus, Erik
    Nowakowski, Grzegorz S.
    Conte, Michael J.
    Bowen, Deborah A.
    Aitken, Casey N.
    Van Dyke, Daniel L.
    Greipp, Patricia T.
    Liu, Xin
    Wu, Xiaosheng
    Zhang, Henan
    Secreto, Charla R.
    Tian, Shulan
    Braggio, Esteban
    Wellik, Linda E.
    Micallef, Ivana
    Viswanatha, David S.
    Yan, Huihuang
    Chanan-Khan, Asher A.
    Kay, Neil E.
    Dong, Haidong
    Ansell, Stephen M.
    BLOOD, 2017, 129 (26) : 3419 - 3427
  • [2] Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL
    Kadri, Sabah
    Lee, Jimmy
    Fitzpatrick, Carrie
    Galanina, Natalie
    Sukhanova, Madina
    Venkataraman, Girish
    Sharma, Shruti
    Long, Brad
    Petras, Kristin
    Theissen, Megan
    Ming, Mei
    Kobzev, Yuri
    Kang, Wenjun
    Guo, Ailin
    Wang, Weige
    Niu, Nifang
    Weiner, Howard
    Thirman, Michael
    Stock, Wendy
    Smith, Sonali M.
    Nabhan, Chadi
    Segal, Jeremy P.
    Lu, Pin
    Wang, Y. Lynn
    BLOOD ADVANCES, 2017, 1 (12) : 715 - 727
  • [3] Richter transformation of CLL
    Jain, Nitin
    Keating, Michael J.
    EXPERT REVIEW OF HEMATOLOGY, 2016, 9 (08) : 793 - 801
  • [4] Revisiting Richter transformation in the era of novel CLL agents
    Petrackova, Anna
    Turcsanyi, Peter
    Papajik, Tomas
    Kriegova, Eva
    BLOOD REVIEWS, 2021, 49
  • [5] Updates in the Management of Richter Transformation
    Rippel, Noa
    Sheppard, Richard
    Kittai, Adam S.
    CANCERS, 2025, 17 (01)
  • [6] Relapsed CLL: sequencing, combinations, and novel agents
    Brown, Jennifer R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2018, : 248 - 255
  • [7] Approaches for relapsed CLL after chemotherapy-free frontline regimens
    Roeker, Lindsey E.
    Mato, Anthony R.
    HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM, 2020, (01) : 10 - 17
  • [8] Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)
    Odetola, Oluwatobi
    Ma, Shuo
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2023, 18 (05) : 130 - 143
  • [9] Richter transformation in Chronic Lymphocytic Leukemia
    Innocenti, Idanna
    Benintende, Giulia
    Tomasso, Annamaria
    Fresa, Alberto
    Autore, Francesco
    Larocca, Luigi Maria
    Laurenti, Luca
    HEMATOLOGICAL ONCOLOGY, 2023, 41 (03) : 293 - 300
  • [10] Treatment of Richter's Transformation with Novel Therapies
    Bajwa, Amneet
    Habib, Alma
    Kittai, Adam S.
    CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2024, 19 (02) : 45 - 55
12345